PROGRESS: Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
Study Details
Study Description
Brief Summary
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical study in women aged 35 to 42 years. This study will investigate the safety and efficacy of Progesterone-IBSA to support euploid embryo blastocyst implantation and early pregnancy after frozen embryo transfer (FET) in a modified natural cycle as a treatment for infertile women. Subjects will be randomized to receive either active Progesterone-IBSA or Crinone 8% for luteal and early pregnancy support and these two groups will be compared.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Investigational Progesterone-IBSA 25mg, twice daily (BID) subcutaneous (SC) injection every 12 hours and Crinone Placebo, once daily (QD) intravaginally. |
Drug: Progesterone-IBSA Injectable Solution
Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
Other Names:
Drug: Placebo Vaginal gel with applicator
Vaginal gel Placebo, once daily (QD) intravaginally
|
| Active Comparator: Comparator Crinone 8%, 90 mg, QD intravaginally and Progesterone-IBSA Placebo, BID SC Injection every 12 hours |
Drug: Progesterone Vaginal Gel with Applicator
Crinone 8%, 90 mg, QD intravaginally
Other Names:
Drug: Placebo injectable solution
Placebo injectable solution, BID SC Injection every 12 hours
|
Outcome Measures
Primary Outcome Measures
- Clinical pregnancy rate [5 weeks post-embryo transfer]
defined by the presence of an intrauterine fetal heart beat
- Ongoing pregnancy [10 weeks post-embryo transfer]
defined by the presence of an ongoing intrauterine pregnancy with fetal heart beat
Secondary Outcome Measures
- Positive pregnancy rate [10+/-2 days after embryo transfer.]
positive serum β-human chorionic gonadotropin (hCG) test rate
- Implantation rate [6 weeks after embryo transfer,]
defined by the number of gestational sacs observed at Visit 6 by means of a transvaginal ultrasound (TVUS), divided by the number of blastocysts transferred (%)
- Delivery rate [2-4 weeks post expected delivery date.]
defined as the number of deliveries with at least one live birth or stillbirth (%)
- Live birth rate [2-4 weeks post expected delivery date.]
defined as the complete expulsion or extraction from a woman of a product of fertilization, after 22 completed weeks of gestational age; which, after such separation, breathes or shows any other evidence of life
- Cycle cancellation rate (with reason) [from treatment start until 10 weeks of pregnancy]
defined as number of subjects dropping form the study at any time.
- Adverse Events related to the mother [from Informed consent signature until 2-4 week after delivery.]
frequency and severity of adverse events related to the mother.
- Local tolerability [from the 4th day of treatment administration until 10 weeks post embryo transfer.]
At each visit, the subject will be queried about the presence of local reactions at administration site (pain, redness, swelling and itching at injection site and pain, irritation, swelling and leakage in the genital area). Events will be described in term of nature, severity (mild, moderate, severe, or very severe) and duration (persisted for up to 1 hour, persisted for more than 1 up to 4 hours, persisted for more than 4 up to 12 hours, persisted for more than 12 hours).
- Early Miscarriage rate [from 5 weeks post embryo transfer until the 12th week of pregnancy.]
defined as a spontaneous loss of an intra-uterine pregnancy
- Late miscarriage rate [after the 12th week of pregnancy until delivery.]
defined as a spontaneous loss of an intra-uterine pregnancy
- Ectopic pregnancy rate [from 5 weeks post embryo transfer until the 12th week of pregnancy.]
defined as a pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualization or histopathology.
- Adverse events related to the newborn. [2-4 weeks after expected delivery.]
frequency and severity of adverse events related to the newborn.
Other Outcome Measures
- Progesterone Pharmacokinetic (PK) characterization [4 days after treatment start.]
Blood sampling to assess Progesterone levels will be collected in order to characterize the PK profile at steady state in the target population
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Both the female subject and their partner (if applicable) have given written informed consent;
-
Premenopausal women 35 to 42 years of age at the time of consent (at least 35 [including day of birthday] and no more than 42 [up to the day before their 43rd birthday]);
-
Valid indication for IVF treatment (i.e. history of infertility according to ASRM definition, single women or same-sex couples);
-
Consistent, regular spontaneous ovulatory menstrual cycle with normal length (24-38 days included);
-
Body mass index (BMI) < 38 kg/m2;
-
Subject with at least one euploid frozen blastocyst from a previous IVF treatment cycle;
-
Less than 3 previous consecutive euploid blastocyst transfers without a life birth;
-
Baseline Follicle Stimulating Hormone (FSH) < 15 mIU/mL, Estradiol (E2) <70 pg/mL and Anti Muellerian Hormone (AMH) >0.7 ng/mL (within 6 months from frozen embryo transfer [FET]);
-
Semen used during IVF was produced by ejaculation (not surgically derived sperm) from either the partner or from a sperm donor. Donor must be 18-40 years of age at the time of collection and compliant with 21 Code of Regulations (CFR) section 1271 Subpart C;
-
Hysterosalpingography, hysteroscopy, 3D ultrasound or sonohysterogram documenting a normal uterine cavity within the last year;
-
Normal cervical cytology/High Risk human papillomavirus (HPV) testing per American College of Obstetricians and Gynecologists guidelines.
Exclusion Criteria:
-
Oligo or anovulation (spontaneous menses > 39 days apart);
-
Breastfeeding or Pregnancy;
-
Contraindication to pregnancy (i.e. an active, uncontrolled clinically significant medical condition or abnormality of the sexual organs determined by the provider);
-
Known family history of major congenital anomalies;
-
Moderate to severe endometriosis (stage 3 or 4);
-
Presence of a unilateral or bilateral hydrosalpinx that communicates with the uterus, that has not been ligated prior to treatment;
-
Recurrent pregnancy loss (RPL) as defined by the American Society of Reproductive Medicine (ASRM) as two or more consecutive failed clinical pregnancies;
-
Presence of a submucosal or intramural fibroid > 4 cm which distorts the uterine cavity or are > 5 cm in diameter;
-
Untreated uterine pathology that could impair embryo implantation (i.e. scarring/Asherman's syndrome or intra uterine polyps > 1 cm in size);
-
Type 1 or 2 diabetes mellitus based on American Diabetes Association (ADA) criteria3;
-
Uncontrolled adrenal or thyroid dysfunction;
-
History of conditions (i.e. toxic shock syndrome) that would contraindicate use of a vaginal progesterone product;
-
Subjects with hepatic impairment (liver function tests > 2x upper limit of normal);
-
Subjects with renal impairment (estimated creatinine clearance <60 mL/min/1.73 m2);
-
History of an active or treated autoimmune disease (i.e. systemic lupus erythematosus);
-
History of arterial disease (i.e. Prior or active thrombophlebitis, thromboembolic disorder or known thrombophilia);
-
Neoplasias (current) or history of neoplasia that may be responsive to progesterone;
-
High grade cervical dysplasia;
-
Undiagnosed vaginal bleeding (i.e. at the time of screening);
-
Use of donor eggs or plans to use a gestational carrier;
-
Use of endometrial receptivity array (ERA) test to postpone or anticipate the embryo transfer (ET) day;
-
Use of epididymal, testicular , electro-ejaculated or chemotherapy exposed sperm;
-
Known allergy to progesterone preparations or their excipients;
-
Current dependence on alcohol, tobacco (must not be smoking/using tobacco x 2 months before the study) or drugs or psychotropic medications;
-
Use of concomitant medications that might interfere with the study evaluation (Use of insulin sensitizing agents, lithium, vaginal medications/preparations, any drugs for luteal support other than those specified in the protocol, Aspirin, Any hormonal treatment within 1 month before the start of ovarian stimulation, with the exception of levothyroxine);
-
Participation in a concurrent clinical trial or in another investigational drug trial within the past 2 months-
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- IBSA Institut Biochimique SA
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 20US-Prg03